Acrivon Therapeutics, Inc. (NasdaqGM: ACRV)
Health Care · Biotechnology · US
$2.20
-0.45% today · +62.5% 1Y
Acrivon Therapeutics, Inc. (NasdaqGM: ACRV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $94.71M and employs 75 people.
Over the last twelve months the share price has gained 62.5%, trading between 1.27 and 3.56.
Tweenvest scores Acrivon Therapeutics, Inc. across four factors: quality 27/100. Its strongest factor is quality.
ACRV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $94.71M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.88
- Dividend yield
- —
- Beta (5Y)
- 1.86
- 52-week high
- $3.56
- 52-week low
- $1.27
- Avg volume (3M)
- —
- Shares outstanding
- 42.85M
- Employees
- 75
- Next earnings
- —
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
- ISIN
- US0048901096
- Founded
- 2018
- Listed since
- Nov 15, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.